Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q2 FY22 results · Jul–Sep 2021
Alkem Laboratories reported revenue from operations of ₹2,799.99 crore (up 18.5% from Q2 FY21) and net profit of ₹558.53 crore (up 16.0% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,799.99 | 2,362.80 | +18.5% | 2,731.36 | +2.5% |
| Other income | 41.96 | 35.54 | +18.1% | 46.65 | −10.1% |
| Total income | 2,841.95 | 2,398.34 | +18.5% | 2,778.01 | +2.3% |
| Profit before tax | 581.54 | 547.75 | +6.2% | 556.12 | +4.6% |
| Net profit for the period | 558.53 | 481.51 | +16.0% | 480.23 | +16.3% |
| Attributable to shareholders of the company | 544.26 | 472.06 | +15.3% | 468.12 | +16.3% |
| EPS, basic (₹) | 45.52 | 39.48 | +15.3% | 39.15 | +16.3% |
| Net margin (%) | 19.9 | 20.4 | 17.6 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,363.99 | 1,984.10 | +19.1% | 2,278.67 | +3.7% |
| Other income | 43.21 | 24.84 | +74.0% | 39.21 | +10.2% |
| Total income | 2,407.20 | 2,008.94 | +19.8% | 2,317.88 | +3.9% |
| Profit before tax | 568.73 | 552.73 | +2.9% | 529.00 | +7.5% |
| Net profit for the period | 558.01 | 495.20 | +12.7% | 469.27 | +18.9% |
| EPS, basic (₹) | 46.67 | 41.42 | +12.7% | 39.25 | +18.9% |
| Net margin (%) | 23.6 | 25.0 | 20.6 |
Consolidated
- Filed with BSE
- 12 Nov 2021, 18:17 IST
- Board meeting
- 12 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Nov 2021, 18:17 IST
- Board meeting
- 12 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE